Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00

Immunome (NASDAQ:IMNM) had its price objective reduced by Stephens from $33.00 to $30.00 in a research note released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities analysts also recently commented on the company. Evercore lifted their price target on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. HC Wainwright initiated coverage on Immunome in a research report on Thursday, February 12th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Leerink Partners set a $40.00 price target on Immunome in a report on Monday, December 15th. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.33.

Immunome Price Performance

NASDAQ IMNM opened at $21.04 on Wednesday. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -8.69 and a beta of 2.12. Immunome has a 12 month low of $5.15 and a 12 month high of $27.65. The company’s fifty day moving average price is $22.74 and its two-hundred day moving average price is $17.67.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. As a group, analysts anticipate that Immunome will post -2.21 EPS for the current year.

Insider Activity at Immunome

In related news, CEO Clay B. Siegall bought 4,729 shares of the firm’s stock in a transaction on Tuesday, December 30th. The stock was bought at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the purchase, the chief executive officer directly owned 665,254 shares in the company, valued at approximately $14,070,122.10. The trade was a 0.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Isaac Barchas sold 383,200 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.74, for a total value of $8,330,768.00. Following the transaction, the director directly owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. This trade represents a 15.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders acquired a total of 68,518 shares of company stock valued at $1,453,958 in the last quarter. Insiders own 7.69% of the company’s stock.

Institutional Trading of Immunome

Several hedge funds have recently made changes to their positions in the stock. Assetmark Inc. bought a new position in Immunome during the 3rd quarter worth $39,000. BNP Paribas Financial Markets lifted its stake in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares during the last quarter. Strs Ohio acquired a new position in shares of Immunome during the fourth quarter valued at $64,000. Tower Research Capital LLC TRC boosted its holdings in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after acquiring an additional 3,802 shares during the period. Finally, BIT Capital GmbH bought a new position in shares of Immunome during the third quarter worth about $69,000. Institutional investors own 44.58% of the company’s stock.

Immunome News Summary

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 quarterly EPS forecasts (Q1: from ($0.68) to ($0.53); Q2: ($0.70) to ($0.55); Q3: ($0.72) to ($0.56); Q4: ($0.68) to ($0.58)) and lifted FY2026 estimate to ($2.21) from ($2.78). These narrower loss projections suggest better near‑term operating performance. Article Link
• Positive Sentiment: HC Wainwright also boosted FY2027 (from ($2.20) to ($1.81)) and FY2028 (from ($0.79) to ($0.54)) estimates, implying a faster path toward profitability than previously modeled — a material positive for valuation assumptions. Article Link
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $40 price target while raising FY2029 and FY2030 profit forecasts (FY2029: $0.69 from $0.63; FY2030: $1.35 from $1.28), reinforcing a bullish long‑term view that likely helped buying interest. Article Link
• Neutral Sentiment: Despite the upgrades, HC Wainwright still models losses through FY2028 (FY2026 consensus remains around ($2.21)), so the company is viewed as a longer‑duration growth/turnaround investment rather than near‑term profitable. Article Link

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.